Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043132 · ClinicalTrials.gov registry record · Phase 2
Tranexamic Acid in Reverse Total Shoulder Arthroplasty
A Phase 2 study, sponsored by Corewell Health East.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT02043132 is a Phase 2 study that has completed, run by Corewell Health East. The registered enrollment target is 116 participants.
The verdict
NCT02043132, a Phase 2 study, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
To the Investigators' knowledge, TXA has not been studied in the setting of reverse total shoulder arthroplasty. We propose a double-blinded, randomized, controlled trial comparing perioperative administration of TXA to placebo in the setting of RTSA. The purpose of this study is to examine the efficacy of TXA in reducing overall blood loss and transfusion rates in patients undergoing reverse total shoulder arthroplasty.
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043132
The ClinicalTrials.gov registry entry for NCT02043132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02043132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043132 about?
NCT02043132 is a clinical study titled "Tranexamic Acid in Reverse Total Shoulder Arthroplasty". To the Investigators' knowledge, TXA has not been studied in the setting of reverse total shoulder arthroplasty. We propose a double-blinded, randomized, controlled trial comparing perioperative administration of TXA to placebo in the setting of RTSA. The purpose of this study is to examine the effi...
What is the current status of trial NCT02043132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2013-09. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02043132?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT02043132?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.